Wieland Voigt

2.1k total citations
61 papers, 1.6k citations indexed

About

Wieland Voigt is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Wieland Voigt has authored 61 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 23 papers in Oncology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Wieland Voigt's work include Cancer therapeutics and mechanisms (13 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Treatments and Mutations (7 papers). Wieland Voigt is often cited by papers focused on Cancer therapeutics and mechanisms (13 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Treatments and Mutations (7 papers). Wieland Voigt collaborates with scholars based in Germany, United States and Austria. Wieland Voigt's co-authors include Hans‐Joachim Schmoll, Karin Jordan, Alexander Stein, Thomas Mueller, Axel Grothey, Wolfram C. M. Dempke, Dirk Arnold, Bridget T. Hill, Thomas Müller and Y M Rustum and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Journal of Medicinal Chemistry.

In The Last Decade

Wieland Voigt

57 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wieland Voigt Germany	21	720	589	300	278	133	61	1.6k
Hao Luo China	24	748 1.0×	360 0.6×	227 0.8×	175 0.6×	159 1.2×	93	1.7k
Hyeong‐Seok Lim South Korea	21	622 0.9×	795 1.3×	280 0.9×	252 0.9×	58 0.4×	91	1.9k
Wolfram C. M. Dempke Germany	20	727 1.0×	727 1.2×	119 0.4×	397 1.4×	109 0.8×	48	1.8k
Scott J. Weir United States	29	928 1.3×	560 1.0×	175 0.6×	213 0.8×	162 1.2×	106	2.2k
Kung‐Kai Kuo Taiwan	22	508 0.7×	317 0.5×	423 1.4×	294 1.1×	114 0.9×	70	1.5k
Li Yu China	21	629 0.9×	689 1.2×	119 0.4×	682 2.5×	121 0.9×	75	1.8k
Livia Bianchi Italy	23	586 0.8×	213 0.4×	167 0.6×	374 1.3×	134 1.0×	35	1.7k
Jianguo Zhi United States	23	746 1.0×	663 1.1×	156 0.5×	274 1.0×	62 0.5×	72	2.2k
Bhaumik B. Patel United States	25	1.3k 1.8×	805 1.4×	157 0.5×	230 0.8×	155 1.2×	62	2.3k
Vincent C. Daniel United States	14	1.3k 1.8×	631 1.1×	497 1.7×	501 1.8×	191 1.4×	23	2.8k

Countries citing papers authored by Wieland Voigt

Since Specialization

Citations

This map shows the geographic impact of Wieland Voigt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wieland Voigt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wieland Voigt more than expected).

Fields of papers citing papers by Wieland Voigt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wieland Voigt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wieland Voigt. The network helps show where Wieland Voigt may publish in the future.

Co-authorship network of co-authors of Wieland Voigt

This figure shows the co-authorship network connecting the top 25 collaborators of Wieland Voigt. A scholar is included among the top collaborators of Wieland Voigt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wieland Voigt. Wieland Voigt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Voigt, Wieland, et al.. (2023). Changes in tidal breathing biomarkers as indicators of treatment response in AECOPD patients in an acute care setting. Advances in Medical Sciences. 68(2). 176–185.

Voigt, Wieland, Helmut Prosch, & Mario Silva. (2023). Clinical Scores, Biomarkers and IT Tools in Lung Cancer Screening—Can an Integrated Approach Overcome Current Challenges?. Cancers. 15(4). 1218–1218. 5 indexed citations

Shuster, Gregory, et al.. (2020). A novel wearable device for monitoring lung function from tidal breathing. 163–163. 1 indexed citations

Su, Chunxia, Mathias Meyer, Robert Pirker, et al.. (2016). From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert Panel. Translational Lung Cancer Research. 5(4). 377–388. 2 indexed citations

Lux, Michael P., et al.. (2013). Economic Constraints - the Growing Challenge for Western Breast Cancer Centers. Breast Care. 8(1). 41–47. 4 indexed citations

Surov, Alexey, Eckhard Fiedler, Wieland Voigt, et al.. (2010). Magnetic resonance imaging of intramuscular metastases. Skeletal Radiology. 40(4). 439–446. 20 indexed citations

Arnold, Dirk, Wieland Voigt, Philipp Kiewe, et al.. (2009). Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. British Journal of Cancer. 101(8). 1241–1247. 23 indexed citations

Voigt, Wieland, et al.. (2008). Severe thrombocytosis and anemia associated with celiac disease in a young female patient: a case report. Journal of Medical Case Reports. 2(1). 96–96. 14 indexed citations

Voigt, Wieland, et al.. (2007). Human Chorionic Gonadotropin-Induced Hyperthyroidism in Germ Cell Cancer – a Case Presentation and Review of the Literature. Oncology Research and Treatment. 30(6). 330–334. 10 indexed citations

10.

Jordan, Karin, Wieland Voigt, & Hans‐Joachim Schmoll. (2006). Chemotherapie-induziertes Erbrechen - Praktische Anleitung zur Prophylaxe und Therapie. DMW - Deutsche Medizinische Wochenschrift. 131(34/35). 1869–1872. 1 indexed citations

11.

Voigt, Wieland, Andrea M. Dietrich, & Hans‐Joachim Schmoll. (2006). Cisplatin und seine Analoga: Übersicht über den Entwicklungsstatus und klinischen Einsatz. Pharmazie in unserer Zeit. 35(2). 134–143. 16 indexed citations

12.

Voigt, Wieland, et al.. (2005). Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. Journal of Cancer Research and Clinical Oncology. 131(9). 585–590. 36 indexed citations

13.

Voigt, Wieland. (2005). Sulforhodamine B Assay and Chemosensitivity. Humana Press eBooks. 110. 39–48. 162 indexed citations

14.

Kellner, O, Wieland Voigt, U Schneyer, Wolfram C. M. Dempke, & Hans‐Joachim Schmoll. (2001). HCG induced hyperthyreosis in germ cell cancer.. PubMed. 20(6D). 5135–8. 8 indexed citations

15.

Dempke, Wolfram C. M., Wieland Voigt, Axel Grothey, Bridget T. Hill, & Hans‐Joachim Schmoll. (2000). Cisplatin resistance and oncogenes - a review. Anti-Cancer Drugs. 11(4). 225–236. 105 indexed citations

16.

Grothey, Axel, et al.. (1999). Biweekly docetaxel (DOC), gemcitabine (GEM), oxaliplatin (LOHP) in heavily pretreated patients with solid tumors — Preliminary results of a phase I study. European Journal of Cancer. 35. S288–S288. 2 indexed citations

17.

Kröger, H., et al.. (1999). Nicotinamide and methionine reduce the liver toxic effect of methotrexate. General Pharmacology The Vascular System. 33(2). 203–206. 19 indexed citations

18.

Grothey, Axel, Wieland Voigt, C. Schöber, et al.. (1999). The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. Journal of Cancer Research and Clinical Oncology. 125(3-4). 166–173. 70 indexed citations

19.

Guo, Bin, Wieland Voigt, U. Vanhoefer, et al.. (1998). Novel cellular determinants for reversal of multidrug resistance in cells expressing P170-glycoprotein. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1401(3). 265–276. 6 indexed citations

20.

Vanhoefer, U., Wieland Voigt, Ralf A. Hilger, et al.. (1997). Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.. PubMed. 9(9). 485–94. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact